購読する
モデル製品
カスタムサービス
創薬研究
コミュ二ティー
huIL18R1/huIL18RAP/huIL18BP Mouse
製品のお見積りを依頼する
当社のカタログから製品を選択してご注文ください。当社チームが詳細な情報をご連絡いたします。
huIL18R1/huIL18RAP/huIL18BP Mouse
製品名
huIL18R1/huIL18RAP/huIL18BP Mouse
製品ID
C002137
系統名
C57BL/6Cya-Il18r1tm1(hIL18R1)Il18raptm1(hIL18RAP)Il18bptm1(hIL18BP)/Cya
背景情報
C57BL/6Cya
状況
このマウス系統を論文で使用する場合は、「huIL18R1/huIL18RAP/huIL18BP Mouse(カタログ番号C002137)はサイアジェンから購入しました。」と引用してください。
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
Cytokine Gene Humanized Mouse Models
Systemic Lupus Erythematosus
Inflammatory Bowel Disease
Rheumatoid Arthritis
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
お見積もりについてはこちらまでご連絡ください
HUGO-GT Humanized Models
Immune Target Humanized Mouse Models
Cytokine Gene Humanized Mouse Models
Systemic Lupus Erythematosus
Inflammatory Bowel Disease
Rheumatoid Arthritis
基本情報
関連リソース
基本情報
遺伝子別名
ACPL, CD218b, IL-1R7, IL18RB, CDw218b, IL-1R-7, IL-18RAcP, IL-1RAcPL, IL-18Rbeta, IL-18R-beta, CD218a, IL18RA, IL1RRP, CDw218a, IL-1Rrp, IL-18Ralpha, IL18Ralpha2, IL-18R-alpha
染色体
Chr 2, Chr 2
MGI ID
さらに
系統詳細
Interleukin-18 (IL-18) is an important pro-inflammatory cytokine that binds to its receptor complex (IL-18Rα encoded by IL18R1 and IL-18Rβ encoded by IL18RAP), activating downstream MyD88/NF-κB and MAPK signaling pathways and playing key regulatory roles in innate and adaptive immunity [1]. The IL18BP (Interleukin 18 Binding Protein) gene encodes a secreted, high-affinity, naturally occurring antagonist of the proinflammatory cytokine IL-18, functioning by binding IL-18 to prevent it from interacting with its receptor, thereby inhibiting IL-18-induced immune responses, such as interferon-gamma (IFN-γ) production [2]. The gene's protein, IL-18BP, is constitutively expressed and secreted primarily by mononuclear cells (such as monocytes/macrophages and T-cells) and is widely expressed at the RNA level in numerous tissues, including the spleen, lung, placenta, and small intestine [3].
The huIL18R1/huIL18RAP/huIL18BP mouse is a triple-gene humanized model obtained by crossing the huIL18R1/huIL18RAP mouse (Catalog No.: C002016) with the huIL18BP mouse (Catalog No.: C001869). The huIL18R1/huIL18RAP/huIL18BP mouse can be utilized for screening, pharmacodynamic evaluation, safety assessment, and mechanism of action studies of multi-target therapeutics targeting the IL-18 receptor complex (IL18R1/IL18RAP) and the natural antagonist of IL-18, IL18BP. It provides an ideal preclinical research platform for developing innovative therapies for inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, and systemic lupus erythematosus (SLE), as well as for tumor immunology-related research.
参考文献
Zhao Y, Tang Y, Zhu X, Hou Y, Li H, Ciccia F, Zou H, Lu L. The Roles of Interleukin-18 in Inflammation and Autoimmune Disease. Clin Rev Allergy Immunol. 2026 Mar 16;69(1):17.
Park SY, Hisham Y, Shin HM, Yeom SC, Kim S. Interleukin-18 Binding Protein in Immune Regulation and Autoimmune Diseases. Biomedicines. 2022 Jul 20;10(7):1750.
Dinarello CA, Novick D, Kim S, Kaplanski G. Interleukin-18 and IL-18 binding protein. Front Immunol. 2013 Oct 8;4:289.
系統作製戦略
The huIL18R1/huIL18RAP/huIL18BP mouse is a humanized model obtained by crossing the huIL18R1/huIL18RAP mouse (Catalog No.: C002016) with the huIL18BP mouse (Catalog No.: C001869).

Figure 1. Gene editing strategy of huIL18R1/huIL18RAP mice. The sequence from exon 1 of the mouse Il18r1 gene to the downstream of exon 13 of the Il18rap gene was replaced with the sequence from exon 1 of the human IL18R1 gene to the downstream of exon 10 of the IL18RAP gene. Since the replaced human genomic fragment contains the SDR42E1P5 pseudogene and MIR4772 microRNA gene, these human genomic elements were also introduced into the mouse genome as part of the humanized region.

Figure 2. Gene editing strategy for huIL18BP mice. The sequences from the start codon to the stop codon of the endogenous mouse Il18bp gene were replaced with the sequences from the start codon to the stop codon of the human IL18BP gene.
適用分野
Multi-target drug screening, pharmacodynamic evaluation, safety evaluation, and mechanism-of-action research targeting the IL-18 receptor complex (IL18R1/IL18RAP) and IL18BP, the natural antagonist protein of IL-18;
Development of innovative therapies for inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriasis, systemic lupus erythematosus (SLE), and tumor immunology-related research.
関連リソース
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
